Boston Scientific Corporation (NYSE:BSX) had its target price upped by investment analysts at BMO Capital Markets from $30.00 to $32.00 in a report issued on Friday, October 27th. The brokerage presently has an “outperform” rating on the medical equipment provider’s stock. BMO Capital Markets’ price target would suggest a potential upside of 12.83% from the company’s current price.
A number of other research analysts have also recently commented on the company. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Boston Scientific Corporation in a research note on Wednesday, August 9th. Cowen and Company restated a “buy” rating and set a $32.00 price objective (up previously from $31.00) on shares of Boston Scientific Corporation in a research note on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific Corporation in a research note on Monday, September 25th. Zacks Investment Research upgraded Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research note on Monday, July 31st. Finally, UBS AG reiterated a “buy” rating and issued a $31.00 price target (up previously from $30.00) on shares of Boston Scientific Corporation in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $30.77.
Boston Scientific Corporation (NYSE BSX) opened at $28.36 on Friday. The firm has a market capitalization of $38,943.84, a P/E ratio of 23.25, a price-to-earnings-growth ratio of 2.19 and a beta of 1.00. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $29.93. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58.
Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.31. The firm had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. Boston Scientific Corporation’s revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.27 earnings per share. equities research analysts predict that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/12/boston-scientific-corporation-bsx-price-target-increased-to-32-00-by-analysts-at-bmo-capital-markets.html.
In other news, EVP Timothy A. Pratt sold 10,104 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $27.46, for a total value of $277,455.84. Following the transaction, the executive vice president now directly owns 185,742 shares of the company’s stock, valued at $5,100,475.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Timothy A. Pratt sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $28.22, for a total transaction of $282,200.00. Following the completion of the transaction, the executive vice president now directly owns 164,681 shares in the company, valued at $4,647,297.82. The disclosure for this sale can be found here. Insiders sold 508,864 shares of company stock valued at $14,581,669 in the last 90 days. Corporate insiders own 0.74% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Acrospire Investment Management LLC increased its position in Boston Scientific Corporation by 157.3% during the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after buying an additional 3,100 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its position in Boston Scientific Corporation by 14.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock worth $160,000 after buying an additional 720 shares during the last quarter. San Francisco Sentry Investment Group CA acquired a new position in Boston Scientific Corporation during the second quarter worth $191,000. Ironwood Investment Counsel LLC acquired a new position in Boston Scientific Corporation during the third quarter worth $204,000. Finally, Perkins Capital Management Inc. acquired a new position in Boston Scientific Corporation during the third quarter worth $204,000. 90.45% of the stock is currently owned by hedge funds and other institutional investors.
Boston Scientific Corporation Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.